UNSPSC 51111746: Ipilimumab

This classification denotes a monoclonal antibody with the molecular formula C6472H9972N1732O2004S40, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6T8C155666, more generally known as ipilimumab. European Medicines Agency schedules ipilimumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB29397. The term IPILIMUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 3, 2006, list 56. Most nations schedule Ipilimumab under HS 30021020 and SITC 54163.

SMILES:. As of Q4 2014, IPILIMUMAB remains the US FDA Preferred Term for this commodity.. Ipilimumab bears US NLM identifiers UMLS ID C1367202 and NCI Concept Code C2654.

UNSPSC 51111746 Ipilimumab is a Commodity code used to classify a specific immunotherapy pharmaceutical product, though recent state and local procurement activity under this code does not align with the code's nominal scope. The two opportunities tagged to this code involve naloxone (an opioid antagonist), doxycycline and ciprofloxacin (antibiotics), and drug deactivation systems — none of which are ipilimumab. State and local governments buying under this code appear to be procurement offices acquiring pharmaceutical inventory and medical countermeasures through cooperative purchasing vehicles and competitive bidding, often with quarterly or regular delivery schedules and fixed-fee pricing structures.

Activity under this code is minimal and geographically dispersed across Florida and Illinois, with no clear repeat buyers evident in the recent record. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical contract through the MMCAP Infuse cooperative to Chartwell Rx LLC on August 28, 2026 (completed award, not an open solicitation) for antibiotic supply over 12 months with renewal options for years 2 and 3. Seminole County, Florida released an IFB on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the due date listed as July 26, 2023 appears to be a data error. Given the mismatch between the code's stated pharmaceutical product and the actual items being procured, this code shows little relevant recent activity for vendors pursuing ipilimumab supply contracts.